Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results